Predicting vinorelbine disposition and toxicity: Does BSA provide more than a "bad statistical association"?

Journal of Clinical Oncology

Volumn 24, Issue 16, 2006, Pages 2412-2413

  Baker, Sharyn D ^a   Sparreboom, Alex ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; RIFAMPICIN; RITONAVIR; VINDESINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLYCOPROTEIN P; VINBLASTINE;

BASAL METABOLIC RATE; BLOOD VOLUME; BODY SURFACE; BONE MARROW SUPPRESSION; CANCER PATIENT; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG TOLERABILITY; EDITORIAL; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; FEASIBILITY STUDY; GLOMERULUS FILTRATION; HUMAN; LEUKOPENIA; NEUTROPENIA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; BODY SIZE; CHEMICALLY INDUCED DISORDER; GENOTYPE; HEMATOLOGIC DISEASE; METABOLISM; NOTE; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY SIZE; BODY SURFACE AREA; FEASIBILITY STUDIES; GENOTYPE; HEMATOLOGIC DISEASES; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; SAMPLE SIZE; VINBLASTINE;

EID: 33745005079     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.4494     Document Type: Editorial

References (16)

1. Ratain MJ: Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit? J Clin Oncol 16:2297-2298, 1998
2. Felici A, Verweij J, Sparreboom A: Dosing strategies for anticancer drugs: The good, the bad and body-surface area. Eur J Cancer 40:1170-1178, 2002
3. Sawyer M, Ratain MJ: Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171-177, 2001
4. Baker SD, Van Schaik RH, Rivory LP, et al: Factors influencing cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10:8341-8350, 2004
5. Baker SD, Verweij J, Rowinsky EK, et al: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 94:1883-1888, 2002
6. Wong M, Balleine RL, Blair EY, et al: Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 24:2448-2455, 2006
7. Matsui K, Masuda N, Uchida Y, et al: Determinants of myelosuppression in the treatment of non-small cell lung cancer with cisplatin-containing chemotherapy. Jpn J Cancer Res 87:781-786, 1996
8. Streetman DS, Bertino JS Jr, Nafziger AN: Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216, 2000
9. Wong M, Evans S, Rivory LP, et al: Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 77:33-42, 2005
10. Press RR, Buckle T, Beijnen JH, et al: The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Cancer Chemother Pharmacol :1-7, 2005 [Epub ahead of print]
11. Leveque D, Wisniewski S, Renault C, et al: The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. Anticancer Res 23:2741-2744, 2003
12. Benet LZ: There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol Interv 5:79-83, 2005
13. Nguyen L, Tranchand B, Puozzo C, et al: Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 53:459-468, 2002
14. Bore P, Rahmani R, van Cantfort J, et al: Pharmacokinetics of a new anticancer drug, navelbine, in patients: Comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother Pharmacol 23:247-251, 1989
15. Wang D, Johnson AD, Papp AC, et al: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics 15:693-704, 2005
16. Puisset F, Dalenc F, Chatelut E, et al: Dexamethasone as a probe for vinorelbine clearance. Br J Clin Pharmacol 60:45-53, 2005